One-Stop Shop: RAD Offers Comprehensive Insights Into AD Diagnosis, Treatment, and Research

“RAD is one-stop shop for everything happening in education, clinical practice, and research for atopic dermatitis,” said Raj Chovatiya, MD, PhD, MSCI, in an interview with Dermatology Times.

Chovatiya, a board-certified dermatologist and clinical associate professor at Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, and a Dermatology Times Editorial Advisory Board member, recently discussed the upcoming Revolutionizing Atopic Dermatitis (RAD) meeting in Nashville, Tennesse, June 6-7. Chovatiya will present numerous sessions on biologics, topicals, IL-31 vs IL-13, and more.

In his interview, Chovatiya highlighted the benefits of RAD as a premier destination for education, research, and clinical insights in atopic dermatitis (AD).

“Even if atopic dermatitis specifically isn't your primary interest as far as research or education… You're going to hear all about not only the approved items that are in your therapeutic repertoire, but also the emerging items that are coming out there. They're going to change your therapy,” Chovatiya noted.

The meeting, he explained, offers in-depth coverage of current FDA-approved therapies as well as investigational agents set to expand the treatment paradigm. Beyond pharmacologic updates, RAD provides an opportunity to explore disease burden, comorbidities, and adjacent eczematous conditions such as chronic hand eczema—areas often underrepresented in traditional AD education.

Chovatiya discussed RAD's role not only as an educational forum but also as a multidisciplinary networking opportunity. “RAD is a great place to not only meet people… but also a chance to catch up on research. There’s going to be a lot of great abstracts, posters, and late breakers that can allow you to see what's happening on the cutting edge,” he said, pointing to the emerging data that enable clinicians to stay at the forefront of innovation.

Positioned as a one-stop resource, RAD aims to elevate clinical care, offering clinicians the tools to optimize outcomes across the AD spectrum.

Must-See Sessions From Chovatiya:

• JAK Inhibitors in AD; June 6 - 9:10 am ET
• Topicals and Biologics - When and Why; June 6 - 2:00 pm ET
• Medical Crossfire: IL-31 and IL-13; June 7 - 11:40 am ET

To attend Chovatiya’s sessions and hear from other experts in AD, register for Revolutionizing Atopic Dermatitis in Nashville, Tennessee, June 6-7. Use code DT40 for 40% off your RAD 2025 registration.